ID   SHEPrSNS-032_2000nM
AC   CVCL_RS18
SY   SHEPrSNS-032(2000nM)
DR   cancercelllines; CVCL_RS18
DR   Wikidata; Q54953308
RX   PubMed=27517323;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:91399; N-[5-[(5-tert-butyl-2-oxazolyl)methylthio]-2-thiazolyl]-4-piperidinecarboxamide (SNS-032; BMS-387032).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0524 ! SH-EP
SX   Female
AG   4Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 05-10-23; Version: 8
//
RX   PubMed=27517323; DOI=10.18632/oncotarget.11160;
RA   Loschmann N., Michaelis M., Rothweiler F., Voges Y., Balonova B.,
RA   Blight B.A., Cinatl J. Jr.;
RT   "ABCB1 as predominant resistance mechanism in cells with acquired
RT   SNS-032 resistance.";
RL   Oncotarget 7:58051-58064(2016).
//